Complete reference list (PDF 1191 KB) - Department of Health and ...

4.10 Meningococcal disease
References
1. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA,
Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier, 2008.
2. Communicable Diseases Network Australia (CDNA). Guidelines for the early clinical and public
health management of meningococcal disease in Australia. (Endorsed October 2007). Canberra:
Australian Government Department of Health and Ageing, 2009. Available at:
http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-other-mening-2007.htm
(accessed Aug 2011).
3. Robinson P, Taylor K, Nolan T. Risk-factors for meningococcal disease in Victoria, Australia, in
1997. Epidemiology and Infection 2001;127:261-8.
4. McCall BJ, Neill AS, Young MM. Risk factors for invasive meningococcal disease in southern
Queensland, 2000-2001. Internal Medicine Journal 2004;34:464-8.
5. Jelfs J, Jalaludin B, Munro R, et al. A cluster of meningococcal disease in western Sydney,
Australia initially associated with a nightclub. Epidemiology and Infection 1998;120:263-70.
6. Ferson M, Young L, Hansen G, et al. Unusual cluster of mild invasive serogroup C meningococcal
infection in a university college. [erratum appears in Commun Dis Intell 1999 Oct 28;23(11):305].
Communicable Diseases Intelligence 1999;23:261-4.
7. Robinson P, Taylor K, Tallis G, et al. An outbreak of serogroup C meningococcal disease
associated with a secondary school. Communicable Diseases Intelligence 2001;25:121-5.
8. Jardine A, Truman G, Sheppeard V, et al. A community outbreak of meningococcal serogroup B
disease in western Sydney: the challenges of identification and significance. Communicable
Diseases Intelligence 2009;33:221-4.
9. Australian Government Department of Health and Ageing. National Notifiable Diseases
Surveillance System. Notification rate of meningococcal infection, received from state and
territory health authorities in the period of 1991 to 2010 and year-to-date notifications for 2011.
2011. Available at: http://www9.health.gov.au/cda/source/cda-index.cfm (accessed Aug 2011).
10. Australian Meningococcal Surveillance Programme. Annual report of the Australian
Meningococcal Surveillance Programme, 2009. Communicable Diseases Intelligence
2010;34:291-302.
11. Chiu C, Dey A, Wang H, et al. Vaccine preventable diseases in Australia, 2005 to 2007.
Communicable Diseases Intelligence 2010;34 Suppl:ix-S167.
12. de Voer RM, Mollema L, Schepp RM, et al. Immunity against Neisseria meningitidis serogroup C
in the Dutch population before and after introduction of the meningococcal C conjugate vaccine.
PLoS ONE 2010;5(8):e12144. doi:10.1371/journal.pone.0012144.
13. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the
experience in England and Wales. Vaccine 2009;27 Suppl 2:B20-9.
14. Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate
vaccines on carriage and herd immunity. Journal of Infectious Diseases 2008;197:737-43.
15. Oster P, Lennon D, O‘Hallahan J, et al. MeNZB: a safe and highly immunogenic tailor-made
vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
Vaccine 2005;23:2191-6.
16. O‘Hallahan J, McNicholas A, Galloway Y, O‘Leary E, Roseveare C. Delivering a safe and
effective strain-specific vaccine to control an epidemic of group B meningococcal disease. New
Zealand Medical Journal 2009;122:48-59.
17. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the
meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological
correlates of protection, and modeling predictions of the duration of herd immunity. Clinical and
Vaccine Immunology: CVI 2010;17:840-7.
18. National Advisory Committee on Immunization (NACI). Update on the invasive meningococcal
disease and meningococcal vaccine conjugate recommendations: an Advisory Committee
Statement (ACS). Canada Communicable Disease Report 2009;35(ACS-3):1-39.